Indivior Share Discussion Threads

[gregmorg] 01/11/2017 13:18

I understand a couple of brokers have increased their price target- not that that's anything other than a guide to investor sentiment. Both with a share price figure higher than where we are now.

Numis has a high figure as follows :

" This recommendation for approval significantly de-risks the longer-term investment case, and our target price thus increases to 640p, based on de-risking future cash-flow due to a more normalised discount rate and the assumption of generic film in 2018."

[gregmorg] 01/11/2017 11:47

Yup, as you say, who knows with this one! Good thing is it is increasingly looking a less dangerous/more secure company.

So after the 2nd November we then roll on to that other tester of our investors steel --on the 14th. Will see how that coding scenario has developed . It could be the stock starts to put the days of serious uncertainty behind it. Revenues are looking good and growing very respectably. But what about the veins!~!

Thinking of patience(or apathy!) I have been a little puzzled by GSK's share price performance in recent time but am hoping this baptism of fire gears up/fires up the new CEO. OR what!

As for my other pharma, IMB, I do wish, Steeplejack, I had more noted your disposal some months back and so questioned my own rationale. Good call. Now I am left waiting for Vaping to kick in! Hopefully this is made less painless by a continued good stream of dividends.

Let's see what tomorrow brings on IND . Unfortunately I cannot listen in to the live investors meeting as I have some silly cross country trail commitment. Hopefully I can listen in later in the day.

[steeplejack] 01/11/2017 08:50

Excellent news.Well done Greg.Extraordinary looking chart.I suppose it's back to litigation for the next plummet or spike,who knows.

[sarpanch] 01/11/2017 08:35

Brilliant rise in 2 months. 267 to 414. I have to cash in on this now.

[glenkaz] 01/11/2017 08:31

🤡✌A039; wow! What a turnaround!

[gregmorg] 31/10/2017 21:06

Steeplejack. I understand the Committee vote at the end was 18 for and one against.The latter was on the basis of this was nothing new! This, I hasten to add, is purely my understanding.

I did say this Committee is advisory but it does look as if the recommendation to the FDA is going our way. A few concerns were raised re the results of the 300mg doses( as opposed to the 100mg) and a few small issues that resulted, but this does not appear to have affected the outcome. So possibly it is looking OK!. We both have experiences of erratic share price performance across the financial reporting period so its important to maintain the longer view.

[gregmorg] 30/10/2017 22:50

Thanks Steeplejack. Trouble is it is a weighty document with over 100 pages, many technical, and a heavyweight panel. I understand its relatively positive but that is just one person's interpretation after a quick scan. It's headed

FDA Briefing Document
Joint Meeting of Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee
October 31, 2017
RE: Overview of the October 31, 2017 PDAC/DSARM Joint Meeting on NDA 209819 for RBP-6000 (buprenorphine injectable) for treatment of opioid dependence

[steeplejack] 30/10/2017 22:36

You're a mine of information,Greg!

[gregmorg] 30/10/2017 19:05

Yes, My understanding is Public Committee Meeting relating to the injectable. Committee only provides guidance to the FDA but it maybe weighty. So maybe some speculation results from that!

[sarpanch] 30/10/2017 18:10

Drug review tomorrow? Any thoughts?

[gregmorg] 18/10/2017 13:51

This was, of course, as reported by Reckitt some months ago!

[gregmorg] 18/10/2017 13:44

Extract from this mornings Reckitt Benckiser Trading Statement
"Indivior / RB Pharma related matters:

As noted in Note 9 of our Interim Statement 2017, the Group remains involved in ongoing investigations by the US Department of Justice (DoJ) and the US Federal Trade Commission and related litigation proceedings by certain state attorneys in the US arising from certain matters relating to the RB Pharmaceuticals (RBP) business prior to its demerger in December 2014 to form Indivior plc and may incur liabilities in relation to such matters.

These investigations and related proceedings are continuing and we are in active discussions with the DoJ. As a consequence of these discussions, we recorded a charge of GBP318 million at 30 June 2017 within our discontinued operations line.

The Group remains committed to ensuring these issues are concluded or resolved satisfactorily but we cannot predict with any certainty whether we will be able to reach any agreement with the DoJ or other parties who are involved in any other investigation or in the related proceedings. The final cost for the Group may be materially higher than this reserve."

[steeplejack] 12/10/2017 08:06

Indivior to Announce 2017 Third Quarter and Year-to-Date Results on November 2(nd)

[waldron] 12/10/2017 07:25

10 October 2017

Indivior to Announce 2017 Third Quarter and Year-to-Date Results on November 2(nd)

Slough, UK, and Richmond, VA, 10 October 2017 - Indivior PLC (LON: INDV) today announced that it will release its 2017 third quarter and year-to-date results on November 2(nd) at 11:00 a.m. London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12 noon London time (8:00 a.m. U.S. Eastern) on November 2(nd) .

Access the Live Webcast for the Results Call on November 2nd

The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is hxxps://edge.media-server.com/m6/p/b6jz7h6i. Participants also may access the results presentation telephonically: US participants 1-646-254-3361; international participants 44(0)20-3427-1901. Please reference confirmation number 9592820. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.

Contact:

Jason Thompson

Vice President, Investor Relations

Tel: [phone] or [e-mail]

###

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOREAXENEEAXFFF

(END) Dow Jones Newswires

October 10, 2017 02:00 ET (06:00 GMT)

[steeplejack] 09/10/2017 14:50

Old Mutual have sold 2.65%(19.1m shares) of the equity bringing their holding down to 4.36%.Now we know where Scopia were acquiring their stock.

[glenkaz] 07/10/2017 08:35

Great stuff 🤡👍

[glenkaz] 02/10/2017 07:26

Great recovery rns out 🤡✌A039;

[thaiger] 28/9/2017 12:26

Strange thing happened just now.....I was quote 344p but when I pressed to sell it came up as "unable to obtain quote, please try again or place a limit order"!!??

[waldron] 25/9/2017 08:32

(ShareCast News) - Indivior has struck an out-of-court settlement to resolve litigation over its Suboxone opiate addiction treatment with Mylan Pharmaceuticals.
The UK company had filed the litigation after Mylan's submitted a new drug application to the US Food & Drug Administration seeking approval to market generic versions of Indivior's Suboxone film.

The terms of the settlement are confidential, Indivior said, and will be submitted to the US Federal Trade Commission and Department of Justice for review.

"We are pleased to have amicably settled all outstanding litigation with Mylan," said chief executive Shaun Thaxter.

"The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

"Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it."

As well as against Mylan, earlier this month, the company filed lawsuits against generic drug makers Dr Reddy's, Actavis, Par, Alvogen and Teva, following other patent infringement litigation over earlier issued Suboxone patents with these same companies.

Indivior is also still preparing to launch an appeal after a court ruled against an older patent, meaning generic versions of Suboxone may soon sold in the US once they gain approval from the FDA.

[waldron] 25/9/2017 08:32

(ShareCast News) - Indivior has struck an out-of-court settlement to resolve litigation over its Suboxone opiate addiction treatment with Mylan Pharmaceuticals.
The UK company had filed the litigation after Mylan's submitted a new drug application to the US Food & Drug Administration seeking approval to market generic versions of Indivior's Suboxone film.

The terms of the settlement are confidential, Indivior said, and will be submitted to the US Federal Trade Commission and Department of Justice for review.

"We are pleased to have amicably settled all outstanding litigation with Mylan," said chief executive Shaun Thaxter.

"The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

"Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it."

As well as against Mylan, earlier this month, the company filed lawsuits against generic drug makers Dr Reddy's, Actavis, Par, Alvogen and Teva, following other patent infringement litigation over earlier issued Suboxone patents with these same companies.

Indivior is also still preparing to launch an appeal after a court ruled against an older patent, meaning generic versions of Suboxone may soon sold in the US once they gain approval from the FDA.

[waldron] 25/9/2017 08:31

(ShareCast News) - Indivior has struck an out-of-court settlement to resolve litigation over its Suboxone opiate addiction treatment with Mylan Pharmaceuticals.
The UK company had filed the litigation after Mylan's submitted a new drug application to the US Food & Drug Administration seeking approval to market generic versions of Indivior's Suboxone film.

The terms of the settlement are confidential, Indivior said, and will be submitted to the US Federal Trade Commission and Department of Justice for review.

"We are pleased to have amicably settled all outstanding litigation with Mylan," said chief executive Shaun Thaxter.

"The agreement at once reflects our desire to create further certainty for Indivior and underscores the strength of our intellectual property.

"Further, as recently demonstrated with our newly granted '454 patent, we expect to expand the intellectual property estate for Suboxone Film and vigorously assert and defend it."

As well as against Mylan, earlier this month, the company filed lawsuits against generic drug makers Dr Reddy's, Actavis, Par, Alvogen and Teva, following other patent infringement litigation over earlier issued Suboxone patents with these same companies.

Indivior is also still preparing to launch an appeal after a court ruled against an older patent, meaning generic versions of Suboxone may soon sold in the US once they gain approval from the FDA.